Single-and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 2, 2012, Pages 138-144

  Brown, Kevin C ^a   Patterson, Kristine B ^b   Jennings, Steven H ^a   Malone, Stephanie A ^a   Shaheen, Nicholas J ^b   Asher Prince, Heather M ^b   Spacek, Melissa ^b   Cohen, Myron S ^b   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

darunavir; etravirine; HIV; pharmacokinetics; rectal; ritonavir; semen

Indexed keywords

DARUNAVIR; ETRAVIRINE; RITONAVIR;

ADULT; ARTICLE; CONCENTRATION LOSS; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LOOSE FECES; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BINDING; RECTUM TISSUE; SEMINAL PLASMA; SINGLE DRUG DOSE; TISSUES; URINARY URGENCY;

ADULT; ANTI-HIV AGENTS; HUMAN EXPERIMENTATION; HUMANS; MALE; PLASMA; PYRIDAZINES; RECTUM; RITONAVIR; SEMEN; SULFONAMIDES; YOUNG ADULT;

EID: 84867005260     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825cb645     Document Type: Article

References (28)

1. Joint United Nations Program on HIV/AIDS (UNAIDS). UNAIDS strategy 2011-2015. Available at: http://www.unaids.org/en/strategygoalsby2015/. Accessed September 14, 2011.
2. Division of Human Health Services: Centers for Disease Control and Prevention (CDC). Questions and Answers: The 15% Increase in HIV Diagnoses from 2004-2007 in 34 States and General Surveillance Report Questions. Available at: http://www.cdc.gov/hiv/surveillance/resources/reports/2007report/qa/. Accessed November 1, 2010.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
4. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS. 2001;15:621-627.
5. Bujan L, Daudin M, Matsuda T, et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS. 2004;18:757-766.
6. Rezk NL, White NR, Jennings SH, et al. A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. Talanta. 2009;79:1372-1378.
7. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine; Rockville, MD; 2001. Available from: http://www/fda.gov/cder/guidance/ index.htm. Accessed November 1, 2010.
8. Cao YJ, Ndovi TT, Parsons TL, et al. Effect of semen sampling frequency on seminal antiretroviral drug concentration. Clin Pharmacol Ther. 2008;83:848-856.
9. Mardirossian G, Tagesson M, Blanco P, et al. A new rectal model for dosimetry applications. J Nucl Med. 1999;40:1524-1531.
10. Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics, Inc; 2010. Available at: http://www.prezista.com/sites/default/files/pdf/us-package-insert. pdf. Accessed September 29, 2011.
11. Norvir [package insert]. North Chicago, IL: Abbott Laboratories; 2010. Available at: http://www.rxabbott.com/pdf/norpi2a.pdf. Accessed September 29, 2011.
12. Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics, Inc; 2010. Available at: http://www.intelence-info.com/sites/default/files/pdf/INTELENCE- Booklet-Package-Insert-hcp.pdf. Accessed September 29, 2011.
13. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther. 2010;88:598-609.
14. Cao YJ, Hendrix CW. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin Pharmacol Ther. 2008;83:401-412.
15. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-2321.
16. DeJesus E, Lalezari JP, Osiyemi OO, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther. 2010;15:711-720.
17. Faed EM. Protein binding of drugs in plasma, interstitial fluid and tissues: effect on pharmacokinetics. Eur J Clin Pharmacol. 1981;21:77-81.
18. McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm. 2008;364:213-226.
19. Kakuda TN, Scholler-Gyure M, Workman C, et al. Single-and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther. 2008;13:655-661.
20. Scholler-Gyure M, Kakuda TN, Raoof A, et al. Clinical pharmacokinet-ics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48: 561-574.
21. Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203:1484-1490.
22. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112-114.
23. Cohen J. Tissue says blood is misleading, confusing HIV cure efforts. Science. 2011;334:1614.
24. Kelley CF, Haaland RE, Patel P, et al. HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. J Infect Dis. 2011;204:761-767.
25. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of anti-retroviral therapy with detection of HIV-1 RNA and DNA in the ano-rectal mucosa of homosexual men. AIDS. 2000;14:F69-F75.
26. Schmelzer M, Schiller LR, Meyer R, et al. Safety and effectiveness of large-volume enema solutions. Appl Nurs Res. 2004;17:265-274.
27. Carballo-Dieguez A, Bauermeister JA, Ventuneac A, et al. The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbi-cides. AIDS Behav. 2008;12:860-866.
28. U.S. Department of Veteran Affairs (VA). Prevention for positives. Available at: http://www.hiv.va.gov/provider/manual-primary-care/prevention-for- positives.asp. Accessed March 22, 2011.